Developer docs
API playgroundTry for free, no card

Search company profiles

Ionpath

Full company profile

uuid00025xn

Namestring
Ionpath
Legal namestring
Ionpath, Inc.
Websiteurl
ionpath.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Ionpath, Inc. is a privately held life-sciences tools company founded in 2014 and headquartered in Menlo Park, California (with an additional Sunnyvale office), that develops and commercializes the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform. The technology uses ion beam mass spectrometry to simultaneously image multiple protein targets in tissue samples while preserving sub-cellular spatial context, addressing limitations of traditional proteomics methods that lose spatial information. The company's core product is the MIBI platform, positioned for translational research and precision medicine applications including disease-mechanism studies and biomarker discovery for targeted therapies.

Ionpath's business model centers on instrument placement and related consumables/antibody panels within the spatial proteomics workflow; source material also references a licensing/royalties-type revenue stream tied to the MIBI technology platform. GTM focus is vertical, targeting translational research cores, academic medical centers, and precision medicine programs, with select_customers not publicly disclosed and pricing not disclosed. The company is included among key players in the Spatial Genomics and Transcriptomics market alongside NanoString Technologies, S2 Genomics, and Akoya Biosciences, addressing a market projected to reach USD 905.4M by 2033.

Strategic capital and commercial validation have come from a syndicate of venture investors led by Genoa Ventures and Samsara BioCapital (2020 $18M round), with prior participation from Bruker, NDCapital, Norwich Ventures, Paladin Partners, Bossa Invest, Trancos Ventures, and Vertical Venture Partners, plus a 2022 strategic investment from Thermo Fisher Scientific. Leadership includes CEO Sander Gubbens, co-founders Mike Angelo and Harris Fienberg, CCO Goran Pljevaljcic, and SVP Marketing & Corporate Strategy Brad Nelson. Total disclosed equity raised is approximately $18M, headcount is 11–50, and the company remains private.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial proteomics, tissue imaging technology, multiplexed protein analysis, biopsy analysis, precision medicine research
Industry4 codes
1Single-Cell & Spatial Omics Services
CodeHLAGANACPrimaryYes
2Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
CodeHLAAAMAIPrimaryNo
3Translational Medicine & Biomarkers
CodeHLAIALAFPrimaryNo
4Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
CodeHLAGAEABPrimaryNo
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
Product category
Spatial Proteomics Instruments & Reagents
Social media profiles1 record
Revenue model1 record
1Spatial Proteomics Technology Platform
TypeLicensing Royalties
Description

Revenue appears to be generated through MIBI technology platform for spatial proteomics applications in translational research and precision medicine

pharmiweb.com
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ionpath develops and offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform, a proprietary ion beam imaging technology used to analyze multiple proteins simultaneously in tissue biopsies while preserving spatial context. The platform supports translational research and precision medicine workflows by enabling multiplexed protein analysis that traditional proteomics methods cannot provide.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ionpath offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics technology as its primary product. The MIBI technology enables spatial proteomics analysis for translational research and precision medicine applications.

Product and service1 record
1MIBI Spatial Proteomics Technology
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Akoya Biosciences
TypeDirect peer
Description

Akoya's CODEX and Phenoptics platforms offer multiplexed spatial proteomics on tissue, directly competing with Ionpath's MIBI in translational and pharma research workflows.

2Standard BioTools
TypeDirect peer
Description

Standard BioTools (formerly Fluidigm) markets the Hyperion imaging mass cytometry system for spatial proteomics, a directly comparable multiplexed tissue-imaging modality to MIBI.

3NanoString Technologies
TypeDirect peer
Description

NanoString's GeoMx digital spatial profiling and CosMx SMI platform compete head-to-head with MIBI in spatial biology and is named alongside Ionpath as a key player in the same market.

4Lunaphore
TypeDirect peer
Description

Lunaphore's COMET platform is a fully automated multiplexed spatial proteomics system, directly comparable to Ionpath's MIBI in tissue-based translational research.

5S2 Genomics
TypeDirect peer
Description

S2 Genomics is named alongside Ionpath as a major player in the spatial genomics and transcriptomics market, with overlapping sample-prep and tissue-handling capabilities.

610x Genomics
TypeBroad incumbent
Description

10x's Xenium and Visium spatial platforms make it a broad incumbent in spatial omics, competing with Ionpath for translational and pharma research dollars even though its core technology differs.

7Bruker
TypeBroad incumbent
Description

Bruker is an Ionpath investor and offers timsTOF and MALDI imaging mass spectrometry, providing a broader mass-spec-based alternative to MIBI in spatial proteomics.

8Thermo Fisher Scientific
TypeBroad incumbent
Description

Thermo Fisher made a strategic investment in Ionpath and operates broad life-sciences tools and spatial/imaging workflows that overlap with MIBI's addressable use cases.

9Miltenyi Biotec
TypeBroad incumbent
Description

Miltenyi's MACSima imaging platform and broader cell-biology portfolio position it as a broad incumbent offering multiplexed tissue imaging alternatives to MIBI.

10Leica Microsystems
TypeBroad incumbent
Description

Leica (part of Danaher) provides a range of microscopy and tissue-imaging systems used in translational pathology, representing a broader alternative workflow to MIBI-based spatial proteomics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ionpath

Spatial Proteomics Instruments & Reagentsionpath.com

What Ionpath does

Ionpath, Inc. is a privately held life-sciences tools company founded in 2014 and headquartered in Menlo Park, California (with an additional Sunnyvale office), that develops and commercializes the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform. The technology uses ion beam mass spectrometry to simultaneously image multiple protein targets in tissue samples while preserving sub-cellular spatial context, addressing limitations of traditional proteomics methods that lose spatial information. The company's core product is the MIBI platform, positioned for translational research and precision medicine applications including disease-mechanism studies and biomarker discovery for targeted therapies.

Ionpath's business model centers on instrument placement and related consumables/antibody panels within the spatial proteomics workflow; source material also references a licensing/royalties-type revenue stream tied to the MIBI technology platform. GTM focus is vertical, targeting translational research cores, academic medical centers, and precision medicine programs, with select_customers not publicly disclosed and pricing not disclosed. The company is included among key players in the Spatial Genomics and Transcriptomics market alongside NanoString Technologies, S2 Genomics, and Akoya Biosciences, addressing a market projected to reach USD 905.4M by 2033.

Strategic capital and commercial validation have come from a syndicate of venture investors led by Genoa Ventures and Samsara BioCapital (2020 $18M round), with prior participation from Bruker, NDCapital, Norwich Ventures, Paladin Partners, Bossa Invest, Trancos Ventures, and Vertical Venture Partners, plus a 2022 strategic investment from Thermo Fisher Scientific. Leadership includes CEO Sander Gubbens, co-founders Mike Angelo and Harris Fienberg, CCO Goran Pljevaljcic, and SVP Marketing & Corporate Strategy Brad Nelson. Total disclosed equity raised is approximately $18M, headcount is 11–50, and the company remains private.

Ionpath firmographics

Firmographics
Name
Ionpath
Legal name
Ionpath, Inc.
Website
https://ionpath.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Ionpath industry classification

Industry
Product category
Spatial Proteomics Instruments & Reagents
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
akta.pro primary industry
Single-Cell & Spatial Omics Services (HLAGANAC)
akta.pro secondary industries
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI), Translational Medicine & Biomarkers (HLAIALAF), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

  • Spatial proteomics
  • Tissue imaging technology
  • Multiplexed protein analysis
  • Biopsy analysis
  • Precision medicine research

Where Ionpath is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ionpath business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Spatial Proteomics Technology Platform: Revenue appears to be generated through MIBI technology platform for spatial proteomics applications in translational research and precision medicine

Ionpath product offering

Product offering

Core offering

Ionpath develops and offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform, a proprietary ion beam imaging technology used to analyze multiple proteins simultaneously in tissue biopsies while preserving spatial context. The platform supports translational research and precision medicine workflows by enabling multiplexed protein analysis that traditional proteomics methods cannot provide.

Product overview

Ionpath offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics technology as its primary product. The MIBI technology enables spatial proteomics analysis for translational research and precision medicine applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • MIBI Spatial Proteomics Technology

Companies that use Ionpath

Customer profile

Segments2 records

Ideal customer profiles2 records

Ionpath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Ionpath partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Ionpath competitors and assessment

Company assessment

Direct peers

  • Akoya Biosciences: Akoya's CODEX and Phenoptics platforms offer multiplexed spatial proteomics on tissue, directly competing with Ionpath's MIBI in translational and pharma research workflows.
  • Standard BioTools: Standard BioTools (formerly Fluidigm) markets the Hyperion imaging mass cytometry system for spatial proteomics, a directly comparable multiplexed tissue-imaging modality to MIBI.
  • NanoString Technologies: NanoString's GeoMx digital spatial profiling and CosMx SMI platform compete head-to-head with MIBI in spatial biology and is named alongside Ionpath as a key player in the same market.
  • Lunaphore: Lunaphore's COMET platform is a fully automated multiplexed spatial proteomics system, directly comparable to Ionpath's MIBI in tissue-based translational research.
  • S2 Genomics: S2 Genomics is named alongside Ionpath as a major player in the spatial genomics and transcriptomics market, with overlapping sample-prep and tissue-handling capabilities.

Broad incumbents

  • 10x Genomics: 10x's Xenium and Visium spatial platforms make it a broad incumbent in spatial omics, competing with Ionpath for translational and pharma research dollars even though its core technology differs.
  • Bruker: Bruker is an Ionpath investor and offers timsTOF and MALDI imaging mass spectrometry, providing a broader mass-spec-based alternative to MIBI in spatial proteomics.
  • Thermo Fisher Scientific: Thermo Fisher made a strategic investment in Ionpath and operates broad life-sciences tools and spatial/imaging workflows that overlap with MIBI's addressable use cases.
  • Miltenyi Biotec: Miltenyi's MACSima imaging platform and broader cell-biology portfolio position it as a broad incumbent offering multiplexed tissue imaging alternatives to MIBI.
  • Leica Microsystems: Leica (part of Danaher) provides a range of microscopy and tissue-imaging systems used in translational pathology, representing a broader alternative workflow to MIBI-based spatial proteomics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Ionpath social profiles

Digital presence

Ionpath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ionpath leadership team

Management profile

Number of profiles

Profiles6 records

Ionpath funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ionpath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ionpath

What does Ionpath do?

Ionpath develops and offers the MIBI (Multiplexed Ion Beam Imaging) spatial proteomics platform, a proprietary ion beam imaging technology used to analyze multiple proteins simultaneously in tissue biopsies while preserving spatial context. The platform supports translational research and precision medicine workflows by enabling multiplexed protein analysis that traditional proteomics methods cannot provide.

Is Ionpath a public or private company?

Ionpath is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ionpath founded?

Ionpath was founded in 2014. It employs 11 to 50 people.

Where is Ionpath based?

Ionpath is headquartered in Menlo Park, United States, in the North America region.

How does Ionpath make money?

One revenue line is on record: spatial Proteomics Technology Platform.

Who are Ionpath's main competitors?

Direct peers on record are Akoya Biosciences, Standard BioTools, NanoString Technologies, Lunaphore and S2 Genomics. Broad incumbents are 10x Genomics, Bruker, Thermo Fisher Scientific, Miltenyi Biotec and Leica Microsystems.

Does Ionpath have an API?

No public API is recorded for Ionpath.

What industry is Ionpath in?

Ionpath's product category is Spatial Proteomics Instruments & Reagents. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comIonpath Receives Strategic Investment to Support Spatial Proteomics InnovationIonpath, Inc., a high-definition spatial proteomics company based in Menlo Park, California, announced on May 11, 2022 that Thermo Fisher Scientific has made a strategic investment in the company, with details not disclosed. CEO Sander Gubbens said the funding will advance MIBI technology in translational research and precision medicine, while Thermo Fisher's Iain Mylchreest cited confidence in Ionpath's differentiated approach.PR NewswireIONpath Appoints Sander Gubbens, PhD, as Chief Executive OfficerIONpath, Inc. announced the appointment of Sander Gubbens, PhD, as its new Chief Executive Officer, replacing co-founder Harris Fienberg, PhD. Dr. Gubbens previously served as President of Gatan, where he led the development of the K2 electron counting camera that contributed to Gatan's $925 million acquisition by Ametek from Roper Technologies. He brings over 30 years of experience in life science technology development and commercialization to guide IONpath's expansion in spatial proteomics for immuno-oncology research.PR NewswireGroundbreaking Stanford Skin Cancer Study Uses Multi-Omics Approach Including IONpath High Definition Spatial ProteomicsStanford researchers utilized IONpath's high-definition spatial proteomics platform, MIBI, to map the tumor microenvironment of squamous cell carcinoma at single-cell resolution. The study revealed that specialized cells at the edge of growing skin cancers reduce immune response, providing new insights into drug resistance mechanisms. This multi-omics approach is now being applied to other cancer types to guide the development of novel immunotherapies.PR NewswireIONpath beruft Brad Nelson als Senior Vice President of Marketing and Corporate Strategy ins LeitungsteamIONpath, Inc. announced the appointment of Brad Nelson as Senior Vice President of Marketing and Corporate Strategy, effective immediately. Nelson will lead marketing, product management, and applications functions to support growing demand for translational medical insights using Multiplexed Ion Beam Imaging (MIBI) technology. He brings over 20 years of experience in life science and medical device organizations, with prior roles at Magnolia Medical Technologies, Labcyte Inc. (acquired by Danaher Corporation), and Velocity11 Inc. (acquired by Agilent Technologies).PR NewswireIONpath nombra a Brad Nelson vicepresidente de Marketing y Estrategia CorporativaIONpath, Inc. has appointed Brad Nelson as Senior Vice President of Marketing and Corporate Strategy to lead marketing, product management, and application functions for its Multiplexed Ion Beam Imaging (MIBI™) technology platform. Nelson brings over 20 years of experience in life sciences and medical device organizations, with a track record that includes driving 70% annual revenue growth at Magnolia Medical Technologies and leading companies through acquisitions by Danaher Corporation and Agilent Technologies. The appointment aims to support IONpath's commercial expansion in immuno-oncology and adjacent precision medicine markets.PR NewswireIONpath designa a Brad Nelson para su equipo de liderazgo, como vicepresidente senior de Marketing y Estrategia CorporativaIONpath, Inc. appointed Brad Nelson as Senior Vice President of Marketing and Corporate Strategy to lead marketing, product management, and applications efforts. This strategic hire aims to address the growing demand for multiplexed ion beam imaging (MIBI) in translational medicine, particularly within the immunooncology sector. The appointment positions IONpath to expand its commercial reach with pharmaceutical, biotechnology, and academic partners.PR NewswireIONpath contrata Brad Nelson para sua equipe de liderança como vice-presidente sênior de marketing e estratégia corporativaIONpath, Inc. announced the appointment of Brad Nelson as Senior Vice President of Marketing and Corporate Strategy. Nelson will lead marketing, product management, and applications functions to address growing demand for multiplexed ion beam imaging (MIBI™) technology in translational medicine and immuno-oncology markets. Nelson brings over 20 years of experience in life sciences and medical devices, having previously served as VP of Marketing at Magnolia Medical Technologies and held leadership roles at Labcyte Inc. and Velocity11 Inc.PR NewswireIONpath nomme Brad Nelson au sein de son équipe de direction au poste de directeur général adjoint du marketing et de la stratégie d'entrepriseIONpath, Inc. announced the appointment of Brad Nelson as Senior Vice President of Marketing and Corporate Strategy to lead marketing, product management, and applications activities for the company's MIBI spatial imaging technology. Nelson brings over 20 years of experience in life sciences and medical devices, most recently serving as VP of Marketing at Magnolia Medical Technologies where he drove over 70% annual revenue growth for the Steripath brand. The appointment is aimed at supporting IONpath's commercial expansion to meet growing demand from academic, pharmaceutical, and biotechnology partners in the immuno-oncology and translational medicine markets.PR NewswireIONpath appoints Brad Nelson to its leadership team as Senior Vice President of Marketing and Corporate StrategyIONpath, Inc. announced the appointment of Brad Nelson as Senior Vice President of Marketing and Corporate Strategy, effective June 2020. Nelson will lead marketing, product management and application functions to support the company's commercial growth in the multiplexed spatial tissue imaging market, particularly in immuno-oncology. Nelson brings over twenty years of experience in life science and medical device organizations, including prior leadership roles at Magnolia Medical Technologies, Labcyte Inc., and Velocity11 Inc.PR NewswireIONpath und Bristol Myers Squibb verfassen gemeinsamen Artikel zur Komplexität von Tumor-Mikroumgebungen für die Fachzeitschrift Laboratory InvestigationIONpath, Inc. and Bristol Myers Squibb jointly authored a scientific article titled "Multiplexed Ion Beam Imaging (MIBI) for Characterization of the Tumor Microenvironment Across Tumor Types" published in the journal Laboratory Investigation. Bristol Myers Squibb provided IONpath with 50 tumor samples stained with 15 metal isotope-tagged antibodies, which IONpath analyzed using its MIBI technology to identify cell phenotypes and map their spatial distribution within the tumor microenvironment. The study demonstrates a method to calculate distances between immune and cancer cells and measure protein expression levels relevant to immunotherapies targeting checkpoints such as PD-1 and PD-L1.